Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

FDA panel backs Pfizer and Celltrion's Remicade biosimilar over J&J's objections

A group of independent FDA advisers voted in favor of OK'ing Pfizer and Celltrion's take on the blockbuster inflammation treatment Remicade for all of the reference drug's approved indications, unswayed by protests from Johnson & Johnson.

OrbiMed founder preaches patience amid a biotech slump

Samuel Isaly, co-founder of biotech investment giant OrbiMed Advisors, said biotech's recent dip in valuations will likely start to turn around as Big Pharma--"the guys with cash"--start to swoop in and buy up suddenly affordable assets.

Amplyx ups its B round to $49.2M on the way to the clinical with an antifungal drug

San Diego's Amplyx Pharmaceuticals boosted its Series B fundraise to $49.2 million and expanded its executive ranks, on pace to take its lead antifungal treatment into human trials this year.

With PAH at its peak, Actelion looks to new disease areas for growth

Actelion, the standard bearer in treatments for pulmonary arterial hypertension, is scouting for new disease areas as it rolls out its next potential blockbuster, hoping to keep up its pace of growth by pivoting away from its home base.

Sarepta faces another FDA delay with its much-scrutinized DMD drug

Sarepta Therapeutics, hoping to win approval with a treatment for Duchenne muscular dystrophy, will have to endure a three-month FDA delay before getting final word on its drug.

Biogen joins a GSK-led data-sharing project to make R&D more efficient

Biogen has signed up with a GlaxoSmithKline-founded effort to better understand the underlying biology of disease, hoping to map out better targets for future therapies by collaborating on early-stage research.

Celltrion's take on J&J's Remicade is 'highly similar' to the original, FDA says

FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.

Shire's self-described blockbuster eye drug lines up for FDA do-over

Shire's once-rejected treatment for dry eye disease has another date with the FDA, supported by new data the company believes will get the drug on the market and eventually help bring in more than $1 billion in annual revenue.

OncoGenex slashes 27% of its payroll as its pipeline promise fades

Bothell, WA-based biotech OncoGenex is laying off nearly a third of its workforce to conserve cash as it holds out hope for its lead cancer program in a move designed to keep the doors open until Phase III results come in.

Osiris CEO steps down for 'personal reasons'

Osiris Therapeutics CEO Lode Debrabandere is resigning his position after 10 years at the company, citing "personal reasons."

'